An analyst from Morgan Stanley maintained MorphoSys ADR (NASDAQ: MOR) at to 'underweight' and a price target of $3.50 from a prior price target of %currency%%price%. Prior to this rating,...
A JPMorgan analyst maintained MorphoSys ADR (NASDAQ: MOR) at Underweight and a price target of $3.30 from a prior price target of %currency%%price%. Prior to this rating, MorphoSys ADR had...
Investing.com - MorphoSys ADR (NASDAQ: MOR) reported first quarter EPS of $-0.36, $0.15 better than the analyst estimate of $-0.51. Revenue for the quarter came in at $68.86M versus the...
Investing.com - MorphoSys ADR (NASDAQ: MOR) reported fourth quarter EPS of $8.93, $8.84 better than the analyst estimate of $0.09. Revenue for the quarter came in at $81.6M versus the...
MorphoSys AG (MOR) today announced that the company will stop work and operations on its pre-clinical research programs to optimize its cost structure. While the data from these pre-clinical...
MorphoSys AG (MOR) reported Q3 EPS of EUR3.60, versus EUR3.30 reported last year. Revenue for the quarter came in at EUR85.8 million, versus EUR41.2 million reported last year.
Investing.com - MorphoSys ADR reported on Wednesday third quarter {{erl-1053141||earnings that beat analysts' forecasts and revenue that topped expectations. MorphoSys ADR announced...
Investing.com - MorphoSys ADR reported on Wednesday second quarter {{erl-1053141||earnings that beat analysts' forecasts and revenue that topped expectations. MorphoSys ADR announced...
Investing.com - MorphoSys ADR reported on Wednesday first quarter {{erl-1053141||earnings that missed analysts' forecasts and revenue that fell short of expectations. MorphoSys ADR...
Investing.com - MorphoSys ADR reported on Wednesday first quarter {{erl-1053141||earnings that missed analysts' forecasts and revenue that topped expectations. MorphoSys ADR announced...
Investing.com - MorphoSys ADR reported on Wednesday third quarter {{erl-1053141||earnings that missed analysts' forecasts and revenue that fell short of expectations. MorphoSys ADR...
Investing.com - MorphoSys ADR reported on Wednesday second quarter {{erl-1053141||earnings that beat analysts' forecasts and revenue that fell short of expectations. MorphoSys ADR...
Investing.com - MorphoSys ADR reported on Wednesday first quarter {{erl-1053141||earnings that missed analysts' forecasts and revenue that fell short of expectations. MorphoSys ADR...
Investing.com - MorphoSys ADR reported on Monday fourth quarter {{erl-1053141||earnings that beat analysts' forecasts and revenue that fell short of expectations. MorphoSys ADR announced...
Investing.com - MorphoSys ADR reported on Wednesday third quarter {{erl-1053141||earnings that missed analysts' forecasts and revenue that fell short of expectations. MorphoSys ADR...
Investing.com - MorphoSys ADR reported on Wednesday second quarter {{erl-1053141||earnings that missed analysts' forecasts and revenue that topped expectations. MorphoSys ADR announced...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
